BMJ alleges Boehringer Ingelheim withheld Pradaxa dosing information from regulators

24 July 2014

German family-owned drug major Boehringer Ingelheim has been accused of withholding ‘important analyses’ from regulators regarding its anticoagulant Pradaxa (dabigatran).

The British Medical Journal says Boehringer Ingelheim was not sufficiently forthcoming on potential benefits of monitoring the anticoagulant activity of Pradaxa and adjusting the dose to ensure the drug works safely and effectively as possible. It said: “recommendations for use of new-generation oral anticoagulants may be flawed because regulators did not see evidence showing that monitoring drug plasma levels could improve safety.”

The drug has been linked to several hundred patient deaths and the company has agreed to pay $650 million to settle most US law suits relating to Pradaxa.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK